Tildrakizumab

🧮 Dose calculator

Psoriasis and steroid-responsive dermatoses · Regimen source: FDA Ilumya · 2.2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Ilumya · 8.1

  “Risk Summary Available data from clinical trials, published literature, and pharmacovigilance with ILUMYA use in pregnant women are insufficient to inform a drug associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Ilumya · 8.2

  “Risk Summary There are no data on the presence of tildrakizumab in human milk, the effects on the breastfed infant, or the effects on milk production.”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Ilumya · 8.4

  “Safety and effectiveness of ILUMYA in pediatric patients (<18 years of age) have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Ilumya · 8.5

  “A total of 1083 subjects were exposed to ILUMYA 100 mg during Phase 2 and 3 trials.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.